The most widely used measure of health-related self-efficacy is the Patient Activation Measure (PAM). It is a ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

The new initiative, FDA PreCheck, was developed in response to President Donald Trump’s executive order to accelerate the ...

Many clinical trials struggle to meet their recruitment targets on time or experience high attrition rates, jeopardising the scientific validity, timelines and financial feasibility of drug ...

It is hoped the new formulation will offer patients greater freedom and flexibility compared to the liquid version ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

The Medscape Global team is bringing their leading cardiology education and proven impact to the European Society of ...

Patient engagement is one of the most reliable ways to drive long-term health outcomes and a critical benchmark for ...

The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...

Rezpegaldesleukin, which has already been granted FDA fast track designation for moderate-to-severe atopic dermatitis, is ...

MSD – known as Merck & Co in the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been ...

Eli Lilly has shared positive top-line results from a head-to-head study of its non-covalent Bruton’s tyrosine kinase (BTK) ...